{'fraction_non_alphanumeric': 0.018847006651884702, 'fraction_numerical': 0.0022172949002217295, 'mean_word_length': 5.45, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 2, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Recent Development of Treatment Strategy for Early Breast Cancer

Abstract Strategy of peri-operative chemotherapy for early breast cancer has been changed dramatically during these 10 years. Development of high efficacy regimen with strong cell-killing drugs for reducing the recurrence risk was first priority in our research in the beginning (escalation). After that, selection of proper strength regimen adapting to recurrence risk expectation of each patient was coming to the main stream (de-escalation). As a most recent topic, response guide treatment with neo-adjuvant therapy contributes dramatically for drug development, in which patients with non-pathological response to initial therapy thought to be a proper candidate for additional adjuvant therapy with investigation new drug. In this lecture I would like to summarize the recent changes of treatment strategy for early breast cancer.